Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The state is accusing the insurer of colluding with the broader Blue Cross Blue Shield network to stifle competition and control prices. BCBSM denies the allegations.
The hack, which was revealed earlier this year in a report from Bleeping Computer, is said to have been limited to a legacy server. Oracle denied its cloud environment had been compromised.
Independence Blue Cross, the largest medical insurance provider in the Philadelphia area, does not admit to wrongdoing. It was accused in a lawsuit backed by the U.S. Department of Justice of misrepresenting the severity of patient illnesses to juice risk-adjusted Medicare payments.
With its $350M in new funding, EliseAI said it plans to build out its technology and sales force. It currently works with specialty provider groups to automate practice operations such as scheduling and insurance verification.
Liberator Medical Supply was accused of offering doctors kickbacks, such as discounted and free supplies, in exchange for filling prescriptions with its products.
The last count submitted to HHS in October pegged the number at 100 million. Now that figure sits at 190 million, and the company continues its investigation.
The Centers for Medicare & Medicaid Services appealed a court ruling that ordered the agency to change the star rating for UnitedHealthcare's Medicare Part D plans, which had been reduced due to a disputed phone call. CMS has now dropped the appeal.
When Larry Ellison talks about healthcare AI, people invest. At least, that’s what happened after the Oracle chairman enthused over AI’s potential to cook up vaccines for cancer.
Tim Noel is taking the reins of the insurance giant in the aftermath of the murder of its previous CEO, Brian Thompson. Noel has been with the company since 2007.
The agency found 82 cases of anaphylaxis associated with glatiramer acetate, sold under the brand names Copaxone and Glatopa, including 19 that emerged after patients had been taking these drugs for more than a year.
